Lyell Immunopharma, Inc.
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
LYEL | NDAQ
Overview
Corporate Details
- ISIN(s):
- US55083R1041
- LEI:
- Country:
- United States of America
- Address:
- 201 HASKINS WAY, 94080 SOUTH SAN FRANCISCO
- Website:
- https://lyell.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Lyell Immunopharma, Inc. is a clinical-stage T-cell reprogramming company focused on developing transformative Chimeric Antigen Receptor (CAR) T-cell therapies for patients with solid tumors and hematologic malignancies. The company's scientific platform is designed to overcome key barriers to successful cell therapy, such as T-cell exhaustion, to generate more durable and effective treatments. Lyell is advancing a pipeline of next-generation product candidates targeting cancers with significant unmet medical need. A lead candidate, rondecabtagene autoleucel (ronde-cel), is a dual-targeting CD19/CD20 therapy being evaluated in clinical trials for aggressive large B-cell lymphoma.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Lyell Immunopharma, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Lyell Immunopharma, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Lyell Immunopharma, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
